The DOI matches its Crossref record; 132 of the 135 references it cites were found in a registry or an index.
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Abstract
The concurrence of visceral obesity, insulin resistance and dyslipidaemia comprises the concept of the metabolic syndrome. The metabolic syndrome is an escalating problem in developed and developing societies that tracks with the obesity epidemic. Dyslipidaemia in the metabolic syndrome is potently atherogenic and, hence, is a major risk factor for CVD (cardiovascular disease) in these subjects. It is globally characterized by hypertriglyceridaemia, near normal LDL (low-density lipoprotein)-cholesterol and low plasma HDL (high-density lipoprotein)-cholesterol. ApoC-III (apolipoprotein C-III), an important regulator of lipoprotein metabolism, is strongly associated with hypertriglyceridaemia and the progression of CVD. ApoC-III impairs the lipolysis of TRLs [triacylglycerol (triglyceride)-rich lipoproteins] by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. In the circulation, apoC-III is associated with TRLs and HDL, and freely exchanges among these lipoprotein particle systems. However, to fully understand the complex physiology and pathophysiology requires the application of tracer methodology and mathematical modelling. In addition, experimental evidence shows that apoC-III may also have a direct role in atherosclerosis. In the metabolic syndrome, increased apoC-III concentration, resulting from hepatic overproduction of VLDL (very-LDL) apoC-III, is strongly associated with delayed catabolism of triacylglycerols and TRLs. Several therapies pertinent to the metabolic syndrome, such as PPAR (peroxisome-proliferator-activated receptor) agonists and statins, can regulate apoC-III transport in the metabolic syndrome. Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and CVD risk in the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High ApoC-III levels were shown to increase total triglyceride levels by an accumulation of VLDL and chylomicrons [166–169]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [168]
In the citing paper
“In hypertriglyceridemia, more VLDL particles, as measured by apoB, and larger and more triglyceride-and apoC-III-enriched lipoproteins are found (39,64,65).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Consequently, APOC-III is considered an independent risk factor for cardiovascular disease [30, 31].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [31]
In the citing paper
“In contrast, apo C-III is an inhibitor of LPL, but also of hepatic lipase. Plasma apo C-III concentrations correlate positively with plasma TG [19].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [19]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · cited 1×
“[64] Sacks et al. (2000) 788 men with myocardial infarction Prospective nested, case-control”
BackgroundAalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450
Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat.
Wu, A. L., & Windmueller, H. G. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50321-5 · Cited by 445
Eisenberg, S., Bilheimer, D. W., & Levy, R. I. (1972) · PubMed · Cited by 431
Peroxisome Proliferator-Activated Receptors: From Genes to Physiology
Kliewer, S. A. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.239 · Cited by 425
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
Martin, G., Duez, H., Blanquart, C., Berezowski, V., Poulain, P., Fruchart, J.-C., Najib-Fruchart, J., Glineur, C., & Staels, B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10852 · Cited by 417
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Knopp, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00807-2 · Cited by 401
Seol, W. (1995) · Molecular Endocrinology · doi:10.1210/me.9.1.72 · Cited by 393
The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis
Lambert, G., Amar, M. J. A., Guo, G., Brewer, H. B., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209525200 · Cited by 392
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 358
Karathanasis, S. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6374 · Cited by 358
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339
Havel, R. J., Fielding, C. J., Olivecrona, T., Shore, V. G., Fielding, P. E., & Egelrud, T. (1973) · Biochemistry · doi:10.1021/bi00733a026 · Cited by 332
Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L. C., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321
Maeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309
Kawakami, A., Aikawa, M., Alcaide, P., Luscinskas, F. W., Libby, P., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.106.622514 · Cited by 305
Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.-C., Gonzalez, F. J., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00896-5 · Cited by 268
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419992 · Cited by 260
Fibrinogen and coronary heart disease--what does it mean?
Assmann, G., Schulte, H., Funke, H., & von Eckardstein, A. (1998) · PubMed · Cited by 256
Sehayek, E., & Eisenberg, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55263-7 · Cited by 249
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
Ganji, S. H., Tavintharan, S., Zhu, D., Xing, Y., Kamanna, V. S., & Kashyap, M. L. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300403-jlr200 · Cited by 227
Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Self-citationThe Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis
Ginsberg, H. N., & Huang, L.-S. (2000) · European Journal of Cardiovascular Risk · doi:10.1177/204748730000700505 · Cited by 209
de Silva, H. V., Lauer, S. J., Wang, J., Simonet, W. S., Weisgraber, K. H., Mahley, R. W., & Taylor, J. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42171-5 · Cited by 208
Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Repa, J. J., Lund, E. G., Horton, J. D., Leitersdorf, E., Russell, D. W., Dietschy, J. M., & Turley, S. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007653200 · Cited by 202
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Statin Trials and Goals of Cholesterol-Lowering Therapy
Grundy, S. M. (1998) · Circulation · doi:10.1161/01.cir.97.15.1436 · Cited by 199
Ebara, T., Ramakrishnan, R., Steiner, G., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 191
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184
Clavey, V., Lestavel-Delattre, S., Copin, C., Bard, J. M., & Fruchart, J. C. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.7.963 · Cited by 178
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Lee, S.-J., Campos, H., Moye, L. A., & Sacks, F. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000066131.01313.eb · Cited by 170
Kinnunen, P. K. J., & Ehnholm, C. (1976) · FEBS Letters · doi:10.1016/0014-5793(76)80145-7 · Cited by 166
Gervois, P., Fruchart, J.-C., & Staels, B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0397 · Cited by 161
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Cited by 154
Effects of Respiration and Gravity on Infradiaphragmatic Venous Flow in Normal and Fontan Patients
Hsia, T., Khambadkone, S., Redington, A. N., Migliavacca, F., Deanfield, J. E., & de Leval, M. R. (2000) · Circulation · doi:10.1161/01.cir.102.suppl_3.iii-148 · Cited by 152
Berge, R. K., Madsen, L., Vaagenes, H., Tronstad, K. J., Göttlicher, M., & Rustan, A. C. (1999) · Biochemical Journal · doi:10.1042/bj3430191 · Cited by 148
Ordovás, J. M., Civeira, F., Genest, J. J., Craig, S., Robbins, A. H., MEADE, T., Pocoví, M., Frossard, P. M., Masharan, U., Wilson, P. W. F., et al. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90234-t · Cited by 146
The metabolism of very low density lipoprotein proteins
Eisenberg, S., Bilheimer, D. W., & Levy, R. I. (1972) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(72)90216-0 · Cited by 143
A Mouse Model with Features of Familial Combined Hyperlipidemia
Masucci-Magoulas, L., Goldberg, I. J., Bisgaier, C. L., Serajuddin, H., Francone, O. L., Breslow, J. L., & Tall, A. R. (1997) · Science · doi:10.1126/science.275.5298.391 · Cited by 142
Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A., & Barrett, P. H. R. (2002) · Metabolism · doi:10.1053/meta.2002.33339 · Cited by 137
Self-citationRusso, G. T., Meigs, J. B., Cupples, L. A., Demissie, S., Otvos, J. D., Wilson, P. W. F., Lahoz, C., Cucinotta, D., Couture, P., Mallory, T., et al. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00409-9 · Cited by 137
Jong, M. C., Rensen, P. C. N., Dahlmans, V. E. H., van der Boom, H., van Berkel, T. J. C., & Havekes, L. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32211-2 · Cited by 136
Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00025-x · Cited by 134
Hyperlipidaemia: Diagnosis and Management
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-1-99_2 · Cited by 128
Riches, F. M., Watts, G. F., Naoumova, R. P., Kelly, J., Croft, K. D., & Thompson, G. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800602 · Cited by 126
Self-citationGENESTJR, J., Bard, J., Fruchart, J., Ordovás, J. M., WILSON, P., & Schaefer, E. J. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90109-g · Cited by 122 · cited 1×
“[69] Genest et al. (1991) 145 men with CAD and 135 control men Case-control study ↓ apoC-III in subjects with CAD”
BackgroundMamo, J. C. L., Watts, G. F., Barrett, P. H. R., Smith, D., James, A. P., & Pal, S. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.3.e626 · Cited by 121
Self-citationJonas, A., Sweeny, S. A., & Herbert, P. N. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82151-6 · Cited by 120
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.278 · Cited by 117
Self-citationWillumsen, N., Skorve, J., Hexeberg, S., Rustan, A. C., & Berge, R. K. (1993) · Lipids · doi:10.1007/bf02535987 · Cited by 116
Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Self-citationRiches, F. M., Watts, G. F., Hua, J., Stewart, G. R., Naoumova, R. P., & Barrett, P. H. R. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5925 · Cited by 112
Self-citationHuman apolipoprotein A-I--C-III gene complex is located on chromosome 11.
Bruns, G. A. P., Karathanasis, S. K., & Breslow, J. L. (1984) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.4.2.97 · Cited by 110
Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and Hypertriglyceridemia
Surguchov, A. P., Page, G. P., Smith, L. C., Patsch, W., & Boerwinkle, E. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.8.941 · Cited by 110
Shepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 102
Kawakami, A., Aikawa, M., Nitta, N., Yoshida, M., Libby, P., & Sacks, F. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000249620.68705.0d · Cited by 99
Schoonjans, K., Peinado‐Onsurbe, J., Fruchart, J., Tailleux, A., Fiévet, C., & Auwerx, J. H. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00632-8 · Cited by 94
Nicotinic acid receptor subtypes and their ligands
Soudijn, W., van Wijngaarden, I., & IJzerman, A. P. (2007) · Medicinal Research Reviews · doi:10.1002/med.20102 · Cited by 94
Huff, M. W., Fidge, N., Nestel, P. J., Billington, T., & Watson, B. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37316-8 · Cited by 90
Glangeaud, M. C., Eisenberg, S., & Olivecrona, T. (1977) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(77)90066-2 · Cited by 86
Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 85 · cited 1×
“[68] Gervaise et al. (2000) 188 subjects with Type 2 diabetes Cross-sectional study ↑ apoC-III and apoC-III-LpB in subjects with”
BackgroundTremblay, A. J., Lamarche, B., Cohn, J. S., Hogue, J., & Couture, P. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000216750.09611.ec · Cited by 85
Glangeaud, M. C., Eisenberg, S., & Olivecrona, T. (1976) · PubMed · Cited by 83
von Eckardstein, A., Holz, H., Sandkamp, M., Weng, W., Funke, H., & Assmann, G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115190 · Cited by 82
Mann, C. J., Troussard, A. A., Yen, F. T., Hannouche, N., Najïb, J., Fruchart, J., Lotteau, V., André, P., & Bihain, B. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31348 · Cited by 81
Dallongeville, J., Baugé, E., Tailleux, A., Peters, J. M., Gonzalez, F. J., Fruchart, J., & Staels, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008809200 · Cited by 78
Hunninghake, D. B., Stein, E. A., Bays, H. E., Rader, D. J., Chitra, R., Simonson, S. G., & Schneck, D. W. (2004) · Coronary Artery Disease · doi:10.1097/00019501-200403000-00008 · Cited by 78
Vaith, P., Assmann, G., & Uhlenbruck, G. (1978) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(78)90396-3 · Cited by 74
ApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70
Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600017-jlr200 · Cited by 66
Self-citationTriglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease
Koren, E., Corder, C. N., Mueller, G., Centurion, H., Hallum, G., Fesmire, J., McConathy, W. D., & Alaupovic, P. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05791-9 · Cited by 63 · cited 1×
“[66] Koren et al. (1996) 100 normotensive non-obese and”
Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 63
Self-citationSparks, D. L., & Pritchard, P. H. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38234-1 · Cited by 63
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Rodriguez, C., Steiner, G. A., Mamer, O., & Davignon, J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.011 · Cited by 62
Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?
Barter, P. J., & Rye, K. (2006) · Circulation · doi:10.1161/circulationaha.105.620450 · Cited by 62
Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*
Kosoglou, T., Statkevich, P., Fruchart, J., Pember, L. J. C., Reyderman, L., Cutler, D. L., Guillaume, M., Maxwell, S. E., & Veltri, E. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125004277 · Cited by 61
Chivot, L., Mainard, F., Bigot‐Corbel, E., Bard, J., Auget, J.-L., Madec, Y., & Fruchart, J. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90042-h · Cited by 60
Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism
Mauger, J., Couture, P., Bergeron, N., & Lamarche, B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500455-jlr200 · Cited by 53
Dallinga‐Thie, G. M., Berk-Planken, I. I. L., Bootsma, A. H., Jansen, H., & on behalf of the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1358 · Cited by 51
Fluvastatin Improves Insulin Resistance in Nondiabetic Dyslpidemic Patients
Sönmez, A., Baykal, Y., Kilic, M., Yılmaz, M. İ., Sağlam, K., Bulucu, F., & Kocar, I. H. (2003) · Endocrine · doi:10.1385/endo:22:2:151 · Cited by 49
Lecomte, E., Herbeth, B., Paillé, F., Steinmetz, J., Artur, Y., & Siest, G. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.10.1666 · Cited by 45
Ito, Y., Breslow, J. L., & Chait, B. T. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38224-9 · Cited by 45
Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.
Bukberg, P. R., Le, N., Ginsberg, H. N., Gibson, J. C., Rubinstein, A., & Brown, W. V. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34278-4 · Cited by 44
Ribalta, J., Ville, A. E. L., Vallvé, J.-C., Humphries, S. E., Turner, P. R., & Masana, L. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37189-3 · Cited by 42
Shin, M., Blanche, P. J., Rawlings, R. S., Fernstrom, H. A., & Krauss, R. M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.6.1527 · Cited by 36
Nishida, H. I., Nakanishi, T., Yen, E. A., Arai, H., Yen, F. T., & Nishida, T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67197-2 · Cited by 34
Metabolism of apolipoprotein C-III in normolipemic human subjects
Malmendier, C. L., Lontie, J., Grutman, G., & Delcroix, C. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90288-2 · Cited by 34
Kee, F., Amouyel, P., Fumeron, F., Arveiler, D., Cambou, J., Evans, A., Cambien, F., Fruchart, J., Ducimetière, P., & Dallongeville, J. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00066-0 · Cited by 34
Barr, S. I., Kottke, B. A., & Mao, S. J. T. (1985) · Metabolism · doi:10.1016/0026-0495(85)90068-x · Cited by 32
Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase
Landis, B. A., Rotolo, F. S., Meyers, W. C., Clark, A. B., & Quarfordt, S. H. (1987) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1987.252.6.g805 · Cited by 32
Identification of ApoB-Containing Lipoprotein Families in NIDDM
Alaupovic, P., Bard, J., Tavella, M. J., & Shafer, D. (1992) · Diabetes · doi:10.2337/diab.41.2.s18 · Cited by 32
Tornóci, L., Scheraldi, C. A., Li, X., Ide, H., Goldberg, I., & Le, N. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35742-4 · Cited by 32
Durrington, P. N. (2007) · CRC Press eBooks · doi:10.1201/b13464 · Cited by 32
Cohn, J. S., Rodriguez, C., Jacques, H., Tremblay, M., & Davignon, J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.d300041-jlr200 · Cited by 31
VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein
Brites, F. D., Bonavita, C. D., Cloës, M., Yael, M. J., Fruchart, J., Castro, G. R., & Wikinski, R. L. W. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(97)00193-9 · Cited by 30
ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression
Gerritsen, G., Rensen, P. C. N., Kypreos, K. E., Zannis, V. I., Havekes, L. M., & van Dijk, K. W. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400479-jlr200 · Cited by 27
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women
Fernández, M. L., Metghalchi, S., Vega‐López, S., Conde‐Knape, K., Lohman, T. G., & Cordero‐MacIntyre, Z. (2004) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.07.001 · Cited by 25
Nguyen, M. N., Chan, D. C., Dwyer, K. P., Bolitho, P., Watts, G. F., & Barrett, P. H. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600018-jlr200 · Cited by 23
Self-citationSwahn, E., von Schenck, H., & OLSSON, A. G. (1998) · Clinical Drug Investigation · doi:10.2165/00044011-199815060-00003 · Cited by 21
Archer, W. R., Desroches, S., Lamarche, B., Dériaz, O., Landry, N., Fontaine‐Bisson, B., Bergeron, J., Couture, P., & Bergeron, N. (2005) · Metabolism · doi:10.1016/j.metabol.2005.05.004 · Cited by 19
Takahashi, T., Hirano, T., Okada, K., & Adachi, M. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00202-6 · Cited by 18
Atlas of atherosclerosis : risk factors and treatment
Wilson, P. F. W. (2003) · Current Medicine eBooks · Cited by 15
Dallongeville, J., Baugé, E., Lebel, P., & Fruchart, J. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.2350782.x · Cited by 12
Chen, X., Tian, H., & Liu, R. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.02.020 · Cited by 10
Wahlberg, G., Holmquist, L., Walldius, G., & Annuzzi, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb19590.x · Cited by 10
Desroches, S., Ruel, I. L., Deshaies, Y., Paradis, M.-E., Archer, W. R., Couture, P., Bergeron, N., & Lamarche, B. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602673 · Cited by 9
Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits
Nicolay, A., Lombard, E., Arlotto, E., Saunier, V., Lorec, A., Lairon, D., & Portugal, H. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.04.021 · Cited by 7
Rahimkhani, S., Tran, K. T., Wang, Y., & Yao, Z. (2000) · Cited by 3
Fan, P., Liu, B., Fang, D. Z., & Zhang, R. (1997) · PubMed · Cited by 2
Research works printed but not linked: 4
- Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur. Heart J., 19, M8
- Ginsberg, 1986, Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo, J. Clin. Invest., 78, 1287, 10.1172/JCI112713 · DOI · Paper page
- Sundaram, 2007, New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL, Arteriosclerosis Thrombosis Vascular Biology Annual Conference, P142
- Clavey, 1995, Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E, Arterioscler. Thromb. Vasc. Biol., 15, 963, 10.1161/01.ATV.15.7.963 · DOI · Paper page
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“Plasma apo C-III concentrations correlate positively with plasma TG [19].”
BackgroundLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Metadata
- Authors
- Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F.
- Affiliations
- The University of Western Australia (AU)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2008-04-14
- Volume
- 114
- Issue
- 10
- Pages
- 611-624
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2037283919
- Cited by
- 282
- References
- 135
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 12 · 2023: 11 · 2022: 12 · 2021: 16 · 2020: 18 · 2019: 22 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 10
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (P41EB001975)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, metabolic syndrome, hypertriglyceridemia, dyslipidemia, cardiovascular risk, triglyceride-rich lipoproteins, lipoprotein lipase inhibition, atherosclerosis, PPAR agonists, statins, lipoprotein metabolism
- MeSH terms
- Animals, Humans, Insulin Resistance, Intestinal Mucosa, Liver, Risk Factors, Triglycerides, Hypertriglyceridemia, Metabolic Syndrome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.